Story perspectives

Goldman: Aging China to Propel Pharma, Biotech Stocks

6/24/2026

Summary

Story summary

Goldman Sachs said pharma and biotech firms could be winners from China's aging population, projecting Hong Kong first and mainland China eighth among the fastest-aging economies by 2050.
Analysts said healthcare will see demographic demand and highlighted Bluestar Adisseo, WuXi XDC Cayman, Sichuan Kelun-Biotech Biopharmaceutical and Zai Lab as buy-rated stocks.
WuXi XDC Cayman, Sichuan Kelun-Biotech Biopharmaceutical and Zai Lab trade on Hong Kong exchange and are expected to benefit by 2030.

1 of 1

Story summary

Goldman Sachs said pharma and biotech firms could be winners from China's aging population, projecting Hong Kong first and mainland China eighth among the fastest-aging economies by 2050.
Analysts said healthcare will see demographic demand and highlighted Bluestar Adisseo, WuXi XDC Cayman, Sichuan Kelun-Biotech Biopharmaceutical and Zai Lab as buy-rated stocks.
WuXi XDC Cayman, Sichuan Kelun-Biotech Biopharmaceutical and Zai Lab trade on Hong Kong exchange and are expected to benefit by 2030.